Lubiprostone Capsule
FDA Label NDC 65162-842

34 label sections · Submitted to the FDA by Amneal Pharmaceuticals Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Llc for the product Lubiprostone (NDC 65162-842). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 chronic idiopathic constipation in adults, 1.2 opioid-induced constipation in adult patients with chronic non-cancer pain, 1.3 irritable bowel syndrome with constipation, 2.1 recommended dosage, 2.2 administration instructions, 3 dosage forms and strengths, 4 contraindications, 5.1 nausea, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.